Program
turigrobart
Its studies are mostly in Neuralgia, led by Eli Lilly.
Furthest: phase 2, since Aug 21, 20242 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 20 open or running | phase 2since Aug 21, 2024 | Feb 5, 2023 | none ahead |
- Named in Eli Lilly’s own pipeline as
Turigrobart
, phase 2, as of Oct 29, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 5, 2023First study: phase 1 study in HealthyFirst studyNCT05727072 · 64 enrolled · United States
- Aug 21, 2024Phase 2 study in NeuralgiaNCT06568042 · 558 enrolled · United States, Canada, Germany and more
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06568042Neuralgia · United States, Canada, Germany and more | 2 | Completed | Jan 12, 2026 | 558 |
| NCT05727072Healthy · United States | 1 | Completed | Feb 19, 2024 | 64 |
How it is read
Names in the registry
- “LY3848575”, 3 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.